Spermosens AB (publ) INTERIM REPORT JANUARY - SEPTEMBER 2025

After demonstrating the diagnostic value of JUNO-Checked earlier this year, we have now taken the next steps preparing for the market.

JANUARY 1st – SEPTEMBER 30st 2025

SIGNIFICANT EVENTS DURING THE QUARTER

07-08-2025 Spermosens provides status update following successful clinical study

SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD

04-11-2025 Spermosens receives patent approval in Israel

03-11-2025 Spermosens receives patent approval in Mexico

22-10-2025 Spermosens receives patent approval in Canada

FINANCIAL INFORMATION

Amounts in SEK thousand	2025 Q3	2024 Q3	2025 Q1-Q3	2024 Q1-Q3	2024 Full-Year	Rolling 12 mth
Net sales	–	–	–	–	–	–
Operating profit/loss	-2 355	-2 131	-7 080	-6 790	-9 163	-9 453
- Whereof activated work for own account	144	787	1 061	2 925	2 387	523
Cash and cash equivalents	9 072	129	9 072	129	4 492	9 072
Total Cash flow	-2 745	-4 363	8 413	-4 363	-3 833	8 943
Equity end of period	34 523	21 970	34 523	21 970	12 692	34 523
Balance sheet total	35 587	24 995	35 587	24 995	26 105	35 587
Equity/assets ratio,%	97	88	97	88	49	97
Liquidity ratio,%	927	25	927	25	43	927
No. of shares	3 173 024 065	283 607 120	3 173 024 065	283 607 120	283 607 120	2 287 895 595
Weighted average number of shares, adjusted for dilution effect	3 173 024 065	283 607 120	2 287 895 595	155 322 633	187 569 007	1 411 264 372
Earnings per share, SEK	0,00	-0,01	0,00	-0,05	0,04	-0,01
Number of employees at end of period	4	3	4	3	3	4

CEO's COMMENTS

This year, we have achieved important results in the areas that matter most for Spermosens' development. In the first quarter, we secured financing to support our strategic plans. In the second quarter, we successfully completed our clinical study with our unique technology, JUNO-*Checked*, ahead of the originally estimated timeline. We have attracted considerable interest from established companies, which could become important commercial partners. We have now taken the next steps in optimizing JUNO-*Checked* for the market.

The clinical study concluded in June this year was one of the most important in the company's history. It showed that fertilization rates increase as a function of sperm binding to the Juno protein on the egg, indicating that JUNO-*Checked* may become a key tool for assessing male fertility potential and for diagnosing a large proportion of so-called unexplained infertility cases. The study was conducted using Generation 2 of the JUNO-*Checked* system.

With the diagnostic value of JUNO-*Checked* now clinically demonstrated, we have entered the next stage of adapting the product for the market. At the same time, our partnership discussions are progressing to a deeper and more detailed level, and we are now engaged in dialogue with a growing number of potential commercial partners.

To enable widespread commercial use, we began development of Generation 3 of JUNO-*Checked* this summer. The next-generation system will provide a significantly faster time-to-result and be easier to use. We are also developing solutions that can be automated and scaled, allowing laboratories to process large numbers of samples.

We have chosen to carry out this development in-house to maintain close control of the process. For this purpose, we have established a dedicated laboratory at Medicon Village in Lund. The work is led by our new CTO, a key expert in electrochemistry and biosensors. Our aim is to make JUNO-*Checked* commercially attractive: robust, simple to use, faster and capable of higher throughput. Once Generation 3 is ready, we will validate its clinical and technical performance, as part of the documentation required by regulatory authorities.

It is very positive that our core patent has now been issued in most major markets, including Europe, the United States, Japan, South Korea, Australia, South Africa, Hong Kong, Singapore, Canada, Mexico and Israel.

We remain focused on securing commercial partnerships, with our primary focus on Europe and the United States, while Japan, China and Australia are also highly interesting markets for Spermosens. Our ambition is to enter such agreements next year, and we are in active discussions with companies connected to IVF clinics, sperm banks and centralized laboratory services. License-based partnerships will enable Spermosens to achieve registration and market launch efficiently.

The positive development continues. We are on track with the commercially viable Generation 3 of JUNO-*Checked* and with the expansion of our partnership discussions. We look forward to presenting further progress in both areas. I would finally like to thank our dedicated employees and development partners for their commitment and effort. It is highly encouraging to see important progress being made.



Tore Duvold

Tore Duvold, CEO of Spermosens AB

12 November 2025